Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

45.64USD
25 Apr 2019
Change (% chg)

$1.02 (+2.29%)
Prev Close
$44.62
Open
$45.05
Day's High
$45.75
Day's Low
$44.54
Volume
3,934,396
Avg. Vol
4,915,334
52-wk High
$63.69
52-wk Low
$44.30

Latest Key Developments (Source: Significant Developments)

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb
Friday, 12 Apr 2019 10:33am EDT 

April 12 (Reuters) - Celgene Corp ::CELGENE STOCKHOLDERS APPROVE PROPOSED ACQUISITION BY BRISTOL-MYERS SQUIBB.CELGENE CORP - CELGENE EXPECTS TRANSACTION TO CLOSE IN Q3 OF 2019.CELGENE CORP - APPROXIMATELY 98% OF VOTES CAST, AND OVER 70% OF SHARES OUTSTANDING AND ENTITLED TO VOTE, VOTED IN FAVOR OF TRANSACTION.  Full Article

Bristol-Myers Says It Is Pleased Celgene Reached Settlement With Alvogen On Revlimid Patent Litigation
Friday, 29 Mar 2019 01:33pm EDT 

March 29 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON CELGENE’S SETTLEMENT WITH ALVOGEN ON REVLIMID® PATENT LITIGATION.BRISTOL-MYERS SQUIBB CO - CONFIDENT IN STRENGTH OF OUR COMBINATION WITH CELGENE.BRISTOL-MYERS SQUIBB CO - CO, CELGENE EXPECT TRANSACTION TO CLOSE IN Q3.BRISTOL-MYERS SQUIBB CO - PLEASED THAT CELGENE HAS REACHED A SETTLEMENT WITH ALVOGEN RELATED TO PATENTS FOR REVLIMID.  Full Article

Starboard To Withdraw Proxy Solicitation to Vote Against Bristol-Myers & Celgene Deal
Friday, 29 Mar 2019 12:02pm EDT 

March 29 (Reuters) - Starboard Value LP::STARBOARD ISSUES STATEMENT ON BRISTOL-MYERS.HAS DECIDED TO WITHDRAW ITS PROXY SOLICITATION TO VOTE AGAINST CELGENE TRANSACTION."CONTINUE TO FEEL STRONGLY THAT PROPOSED TRANSACTION BETWEEN BRISTOL-MYERS AND CELGENE CORPORATION IS A BAD DEAL FOR SHAREHOLDERS".CONTINUE TO INTEND TO VOTE SHARES AGAINST BRISTOL-MYERS AND CELGENE DEAL AT UPCOMING SPECIAL MEETING.  Full Article

Bristol-Myers Squibb And Concerto HealthAI Announce Strategic Agreement
Thursday, 28 Mar 2019 08:38am EDT 

March 28 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB AND CONCERTO HEALTHAI ANNOUNCE STRATEGIC AGREEMENT.BRISTOL-MYERS SQUIBB - MULTI-YEAR STRATEGIC AGREEMENT WITH CONCERTO HEALTHAI WILL COVER A DIVERSE RANGE OF CANCERS, INTEGRATE MULTIPLE DATA SOURCES.BRISTOL-MYERS SQUIBB CO - WILL USE CONCERTO HEALTHAI'S PLATFORM, EUREKAHEALTH, TO ACCELERATE INSIGHTS.  Full Article

Starboard Opposes Bristol-Myers' Proposed Acquisition Of Celgene
Tuesday, 19 Mar 2019 07:00am EDT 

March 19 (Reuters) - Bristol-Myers Squibb Co ::STARBOARD ISSUES INVESTOR PRESENTATION OPPOSING BRISTOL-MYERS SQUIBB'S ILL-ADVISED PROPOSED ACQUISITION OF CELGENE.STARBOARD ISSUES INVESTOR PRESENTATION OPPOSING BRISTOL-MYERS SQUIBB'S ILL-ADVISED PROPOSED ACQUISITION OF CELGENE.STARBOARD VALUE SAYS BELIEVES PROPOSED MERGER WITH CELGENE IS NOT IN BEST INTERESTS OF BRISTOL-MYERS SHAREHOLDERS.STARBOARD VALUE SAYS URGES ALL BRISTOL-MYERS SHAREHOLDERS TO REJECT PROPOSED CELGENE TRANSACTION.STARBOARD VALUE SAYS MAILED DEFINITIVE PROXY MATERIALS AND A BLUE PROXY CARD IN CONNECTION WITH BRISTOL-MYERS SQUIBB SPECIAL MEETING OF SHAREHOLDERS.  Full Article

Starboard Now Owns 4.4 Mln Bristol-Myers Shares-Filing
Thursday, 28 Feb 2019 05:16pm EST 

Feb 28 (Reuters) - Bristol-Myers Squibb Co ::ACTIVIST HEDGE FUND STARBOARD SAYS NOW OWNS 4.4 MILLION BRISTOL-MYERS SHARES-FILING.  Full Article

Bristol-Myers Squibb Says Celgene Deal Is The Best Path Forward
Thursday, 28 Feb 2019 06:41am EST 

Feb 28 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB, IN LETTER TO EMPLOYEES ON FEB 27, SAYS "WE ARE VERY DISAPPOINTED BY POSITION OF WELLINGTON MANAGEMENT".BRISTOL-MYERS SQUIBB, IN LETTER TO EMPLOYEES ON FEB. 27, SAYS "BELIEVE THAT THE CELGENE TRANSACTION IS THE BEST PATH FORWARD FOR OUR COMPANY".  Full Article

Bristol-Myers Squibb Co - Employee Workforce Reductions Were About 900 In 2018, 1,900 In 2017 And 1,100 In 2016
Monday, 25 Feb 2019 08:01pm EST 

Feb 25 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB CO - EMPLOYEE WORKFORCE REDUCTIONS WERE ABOUT 900 IN 2018, 1,900 IN 2017 AND 1,100 IN 2016.  Full Article

EU Medicines Agency Recommends Approval Of Pfizer's Vizimpro, Bristol-Myers' Reyataz
Friday, 1 Feb 2019 07:45am EST 

Feb 1 (Reuters) - EMA's CHMP::EU MEDICINES AGENCY RECOMMENDATIONS FOR JAN 2019.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF PFIZER’S LUNG CANCER DRUG VIZIMPRO.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF BRISTOL-MYERS SQUIBB’S HIV DRUG REYATAZ.  Full Article

Celgene Q4 Earnings Per Share $1.50
Thursday, 31 Jan 2019 07:30am EST 

Jan 31 (Reuters) - Celgene Corp ::CELGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS.Q4 REVENUE $4.037 BILLION VERSUS REFINITIV IBES ESTIMATE OF $3.99 BILLION.Q4 EARNINGS PER SHARE $1.50.Q4 EARNINGS PER SHARE ESTIMATE $2.32 -- REFINITIV IBES DATA.REAFFIRMING 2020 FINANCIAL OUTLOOK.REVLIMID SALES FOR Q4 INCREASED 16 PERCENT TO $2,549 MILLION.OZANIMOD U.S. AND EU REGULATORY SUBMISSIONS ON-TRACK FOR Q1 2019.OTEZLA SALES IN Q4 WERE $448 MILLION, A 21 PERCENT INCREASE YEAR-OVER-YEAR.QTRLY ADJUSTED EARNINGS PER SHARE $2.39.BRISTOL-MYERS SQUIBB AND CELGENE EXPECT TO CLOSE TRANSACTION IN Q3 OF 2019.SEES 2019 GAAP DILUTED EPS $8.40 TO $9.08.2019 GUIDANCE FOR TOTAL REVENUE AND NET PRODUCT SALES OF REVLIMID & OTEZLA UNCHANGED FROM GUIDANCE PROVIDED ON JAN. 7.FY2019 EARNINGS PER SHARE VIEW $10.42, REVENUE VIEW $17.00 BILLION -- REFINITIV IBES DATA.  Full Article

Photo

Bristol-Myers profit slightly tops Wall Street view on blood thinner sales

NEW YORK U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.